Related references
Note: Only part of the references are listed.Long term liver specific glucokinase gene defect induced diabetic cardiomyopathy by up regulating NADPH oxidase and down regulating insulin receptor and p-AMPK
Hui Li et al.
CARDIOVASCULAR DIABETOLOGY (2014)
The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes
Rachel J. Perry et al.
NATURE (2014)
Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial
M. Takihata et al.
DIABETES OBESITY & METABOLISM (2013)
Excretion of Berberine and Its Metabolites in Oral Administration in Rats
Jing-Yi Ma et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Quentin M. Anstee et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats
Xiang-Shan Tan et al.
PLOS ONE (2013)
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
A. Astrup et al.
INTERNATIONAL JOURNAL OF OBESITY (2012)
Bioavailability Study of Berberine and the Enhancing Effects of TPGS on Intestinal Absorption in Rats
Wei Chen et al.
AAPS PHARMSCITECH (2011)
Increased Liver Fat Content and Unfavorable Glucose Profiles in Subjects Without Diabetes
Hua Bian et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Mitochondrial Carnitine Palmitoyltransferase 1a (CPT1a) Is Part of an Outer Membrane Fatty Acid Transfer Complex
Kwangwon Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Effects and Action Mechanisms of Berberine and Rhizoma coptidis on Gut Microbes and Obesity in High-Fat Diet-Fed C57BL/6J Mice
Weidong Xie et al.
PLOS ONE (2011)
Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats
Yi-Tong Liu et al.
DRUG METABOLISM AND DISPOSITION (2010)
Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats
XinXia Chang et al.
JOURNAL OF LIPID RESEARCH (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
NAFLD as a Risk Factor for the Development of Diabetes and the Metabolic Syndrome: An Eleven-Year Follow-up Study
Leon A. Adams et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Combined effects of single-nucleotide polymorphisms in GCK, GCKR, G6PC2 and MTNR1B on fasting plasma glucose and type 2 diabetes risk
E. Reiling et al.
DIABETOLOGIA (2009)
Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin. receptor expression
Wei-Jia Kong et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2009)
Berberine decreases PCSK9 expression in HepG2 cells
Jamie Cameron et al.
ATHEROSCLEROSIS (2008)
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
Guruprasad P. Aithal et al.
GASTROENTEROLOGY (2008)
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
Yifei Zhang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Non-alcoholic fatty liver disease: The mist gradually clears
Nimantha Mark Wilfred de Alwis et al.
JOURNAL OF HEPATOLOGY (2008)
Efficacy of berberine in patients with type 2 diabetes mellitus
Jun Yin et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry
Wenyan Hua et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2007)
Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: Executive summary
Geoffrey C. Farrell et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states
Yun S. Lee et al.
DIABETES (2006)
Nonalcoholic fatty liver disease: From steatosis to cirrhosis
GC Farrell et al.
HEPATOLOGY (2006)
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population
LS Szczepaniak et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2005)
Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
WJ Kong et al.
NATURE MEDICINE (2004)
Share Paper
